Cell and Animal Models for SARS-CoV-2 Research
暂无分享,去创建一个
[1] K. To,et al. A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge , 2022, Nature Communications.
[2] T. Pandita,et al. Breakthroughs and Applications of Organ-on-a-Chip Technology , 2022, Cells.
[3] H. S. Rho,et al. A guide to the organ-on-a-chip , 2022, Nature Reviews Methods Primers.
[4] E. Dora,et al. Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model , 2022, Science Translational Medicine.
[5] J. Chan,et al. Animal models in SARS-CoV-2 research , 2022, Nature Methods.
[6] R. Plemper,et al. SARS-CoV-2 variant of concern type and biological sex affect efficacy of molnupiravir in dwarf hamster model of severe COVID-19 , 2022, bioRxiv.
[7] A. García-Sastre,et al. Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs , 2021, mBio.
[8] K. To,et al. Low dose inocula of SARS-CoV-2 Alpha variant transmits more efficiently than earlier variants in hamsters , 2021, Communications Biology.
[9] A. Lorusso,et al. Long‐term persistence of neutralizing SARS‐CoV‐2 antibodies in pets , 2021, Transboundary and emerging diseases.
[10] Robert J. Fischer,et al. SARS-CoV-2 disease severity and transmission efficiency is increased for airborne compared to fomite exposure in Syrian hamsters , 2021, Nature Communications.
[11] A. García-Sastre,et al. Infection and transmission of ancestral SARS-CoV-2 and its alpha variant in pregnant white-tailed deer , 2021, bioRxiv.
[12] N. Hulo,et al. Estimating clinical SARS-CoV-2 infectiousness in Vero E6 and primary airway epithelial cells , 2021, The Lancet Microbe.
[13] Y. Bi,et al. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection , 2021, Nature Communications.
[14] Su-Jin Park,et al. Single-cell transcriptome of bronchoalveolar lavage fluid reveals sequential change of macrophages during SARS-CoV-2 infection in ferrets , 2021, Nature Communications.
[15] Jordan J. Clark,et al. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 , 2021, Nature Communications.
[16] M. Drebot,et al. SARS-CoV-2 infection and transmission in the North American deer mouse , 2021, Nature Communications.
[17] M. Zimic,et al. Evidence of neutralizing antibodies against SARS-CoV-2 in domestic cats living with owners with a history of COVID-19 in Lima – Peru , 2021, bioRxiv.
[18] W. de Lau,et al. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses , 2021, Nature Communications.
[19] D. Altmann,et al. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2 , 2021, npj Vaccines.
[20] D. Altmann,et al. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2 , 2021, npj Vaccines.
[21] Rani K. Powers,et al. A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics , 2021, Nature Biomedical Engineering.
[22] Huanchun Chen,et al. Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice , 2021, EBioMedicine.
[23] G. Ebel,et al. SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for spillback to New World rodents , 2021, PLoS pathogens.
[24] L. Szekely,et al. Cell-type-resolved quantitative proteomics map of interferon response against SARS-CoV-2 , 2021, iScience.
[25] K. Jarnagin,et al. Animal models for SARS-Cov2/Covid19 research-A commentary , 2021, Biochemical Pharmacology.
[26] A. Costa,et al. ACE2 OVEREXPRESSION CHANGES THE SARS-COV-2 INFECTION PROFILE IN BEAS-2B CELLS , 2021, Cytotherapy.
[27] F. Grieder,et al. Nonhuman primate models for SARS-CoV-2 research: Consider alternatives to macaques , 2021, Lab Animal.
[28] Brian T. Emmer,et al. ACE2 protein expression within isogenic cell lines is heterogeneous and associated with distinct transcriptomes , 2021, bioRxiv.
[29] D. Brodie,et al. Post-acute COVID-19 syndrome , 2021, Nature Medicine.
[30] Jin Yu. Organoids: A New Model for SARS-CoV-2 Translational Research , 2021, International journal of stem cells.
[31] A. Nicholson,et al. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19 , 2021, Nature Communications.
[32] J. Miyan,et al. Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. , 2021, Annual review of pharmacology and toxicology.
[33] H. Jäck,et al. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization , 2021, bioRxiv.
[34] T. Rana,et al. Revealing Tissue-Specific SARS-CoV-2 Infection and Host Responses using Human Stem Cell-Derived Lung and Cerebral Organoids , 2021, Stem Cell Reports.
[35] Henrique S. Fernandes,et al. In Silico, In Vitro and In Cellulo Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion , 2021, bioRxiv.
[36] A. Gupta,et al. A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids. , 2021, Journal of the American Society of Nephrology : JASN.
[37] Charles Y. Tan,et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2 , 2021, Nature.
[38] S. Einav,et al. Retracted papers on SARS-CoV-2 and COVID-19 , 2021, British Journal of Anaesthesia.
[39] M. Palmer,et al. Susceptibility of White-Tailed Deer (Odocoileus virginianus) to SARS-CoV-2 , 2021, Journal of Virology.
[40] Qiang Zhou,et al. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells , 2021, Cell Research.
[41] C. Turner,et al. Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity , 2021, Nature Communications.
[42] Xiaozhong Peng,et al. A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome , 2021, Signal Transduction and Targeted Therapy.
[43] P. McPherson,et al. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis , 2021, Journal of Biological Chemistry.
[44] C. Hallam,et al. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets , 2020, Nature microbiology.
[45] Mauro J. Muraro,et al. An organoid‐derived bronchioalveolar model for SARS‐CoV‐2 infection of human alveolar type II‐like cells , 2020, The EMBO journal.
[46] T. Song,et al. SARS-CoV-2 induced intestinal responses with a biomimetic human gut-on-chip , 2020, Science Bulletin.
[47] M. Hoque,et al. Effect of COVID-19 on Lungs: Focusing on Prospective Malignant Phenotypes , 2020, Cancers.
[48] Grace X. Y. Zheng,et al. Progenitor identification and SARS-CoV-2 infection in human distal lung organoids , 2020, Nature.
[49] R. Plemper,et al. Therapeutically Administered Ribonucleoside Analogue MK-4482/EIDD-2801 Blocks SARS-CoV-2 Transmission in Ferrets , 2020, Nature microbiology.
[50] T. Geisbert,et al. Establishment of an African green monkey model for COVID-19 and protection against reinfection , 2020, Nature immunology.
[51] A. Eid,et al. Hydroxychloroquine in COVID-19 Patients: Pros and Cons , 2020, Frontiers in Pharmacology.
[52] A. Gruber,et al. The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection , 2020, Cell Reports.
[53] P. Maes,et al. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters , 2020, Nature Communications.
[54] M. Koopmans,et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans , 2020, Science.
[55] T. Beccari,et al. Pilot study for the evaluation of safety profile of a potential inhibitor of SARS-CoV-2 endocytosis , 2020, Acta bio-medica : Atenei Parmensis.
[56] J. Qiu,et al. Long-Term Modeling of SARS-CoV-2 Infection of In Vitro Cultured Polarized Human Airway Epithelium , 2020, mBio.
[57] Yuanlin Song,et al. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms , 2020, Signal Transduction and Targeted Therapy.
[58] D. O’Connor,et al. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models , 2020, Nature Reviews Immunology.
[59] M. Mohan,et al. Animal Models for SARS-CoV-2 research: A Comprehensive Literature Review. , 2020, Transboundary and emerging diseases.
[60] Jared L. Johnson,et al. Identification of SARS-CoV-2 Inhibitors using Lung and Colonic Organoids , 2020, Nature.
[61] Channabasavaiah B. Gurumurthy,et al. Genetically modified mouse models to help fight COVID-19 , 2020, Nature Protocols.
[62] J. Qin,et al. Biomimetic Human Disease Model of SARS‐CoV‐2‐Induced Lung Injury and Immune Responses on Organ Chip System , 2020, Advanced science.
[63] L. Steinmetz,et al. Single‐cell analyses reveal SARS‐CoV‐2 interference with intrinsic immune response in the human gut , 2020, bioRxiv.
[64] T. Bestebroer,et al. SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets over more than one meter distance , 2020, Nature Communications.
[65] A. Thitithanyanont,et al. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana , 2020, Scientific Reports.
[66] Madeline A. Lancaster,et al. SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids , 2020, Cell Stem Cell.
[67] M. Deininger,et al. Imatinib is not a potent anti-SARS-CoV-2 drug , 2020, Leukemia.
[68] S. Vandewoude,et al. Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats , 2020, Proceedings of the National Academy of Sciences.
[69] Steven M. Holland,et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.
[70] Jacques Fellay,et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.
[71] Lisa E. Gralinski,et al. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice , 2020, Cell.
[72] Lisa E. Gralinski,et al. Animal models for COVID-19 , 2020, Nature.
[73] Catherine Z. Chen,et al. Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium , 2020, Cell Stem Cell.
[74] A. Gruber,et al. SARS‐CoV‐2 infection of Chinese hamsters (Cricetulus griseus) reproduces COVID‐19 pneumonia in a well‐established small animal model , 2020, Transboundary and emerging diseases.
[75] H. Clevers,et al. Establishment of patient-derived cancer organoids for drug-screening applications , 2020, Nature Protocols.
[76] Jay Gopalakrishnan,et al. SARS‐CoV‐2 targets neurons of 3D human brain organoids , 2020, The EMBO journal.
[77] M. Marshall. The lasting misery of coronavirus long-haulers , 2020, Nature.
[78] Rajarshi Pal,et al. Human induced pluripotent stem cell-derived lung epithelial system for SARS-CoV-2 infection modeling and its potential in drug repurposing. , 2020, Stem cells and development.
[79] Lisa E. Gralinski,et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures , 2020, Nature.
[80] W. Dowling,et al. Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients , 2020, Nature Communications.
[81] D. Ho,et al. Modeling COVID-19 with Human Pluripotent Stem Cell-Derived Cells Reveals Synergistic Effects of Anti-inflammatory Macrophages with ACE2 Inhibition Against SARS-CoV-2 , 2020, Research square.
[82] Y. Itoh,et al. Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques , 2020, bioRxiv.
[83] N. Patel,et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge , 2020, bioRxiv.
[84] G. Yuan,et al. Identification of potential key genes for SARS-CoV-2 infected human bronchial organoids based on bioinformatics analysis , 2020, bioRxiv.
[85] Xiaozhong Peng,et al. Comparison of nonhuman primates identified the suitable model for COVID-19 , 2020, Signal Transduction and Targeted Therapy.
[86] D. Diel,et al. SARS-COV-2 INFECTION AND LONGITUDINAL FECAL SCREENING IN MALAYAN TIGERS (PANTHERA TIGRIS JACKSONI), AMUR TIGERS (PANTHERA TIGRIS ALTAICA ), AND AFRICAN LIONS (PANTHERA LEO KRUGERI) AT THE BRONX ZOO, NEW YORK, USA , 2020, Journal of Zoo and Wildlife Medicine.
[87] Shamus P. Keeler,et al. SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function , 2020, Nature Immunology.
[88] Yong-tang Zheng,et al. Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques , 2020, Zoological research.
[89] Wenling Wang,et al. Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells , 2020, Nature Communications.
[90] T. Geisbert,et al. Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase , 2020, Virology Journal.
[91] Yan Li,et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy , 2020, Science.
[92] V. Munster,et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.
[93] V. Munster,et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.
[94] Rebecca J. Loomis,et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates , 2020, The New England journal of medicine.
[95] D. Lauffenburger,et al. Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.
[96] S. Chanda,et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing , 2020, Nature.
[97] S. Tong,et al. From People to Panthera: Natural SARS-CoV-2 Infection in Tigers and Lions at the Bronx Zoo , 2020, mBio.
[98] Yong-tang Zheng,et al. COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2 , 2020, Zoological research.
[99] X. de Lamballerie,et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates , 2020, Nature.
[100] M. Müller,et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 , 2020, Nature.
[101] C. Hallam,et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice , 2020, Nature Communications.
[102] B. Clotet,et al. Pigs are not susceptible to SARS‐CoV‐2 infection but are a model for viral immunogenicity studies , 2020, Transboundary and Emerging Diseases.
[103] Timothy A. Blenkinsop,et al. SARS-CoV-2 Infection of Ocular Cells from Human Adult Donor Eyes and hESC-Derived Eye Organoids. , 2020, SSRN.
[104] H. Mouquet,et al. Syncytia formation by SARS‐CoV‐2‐infected cells , 2020, bioRxiv.
[105] M. Koopmans,et al. Clinical and Pathological Findings in SARS-CoV-2 Disease Outbreaks in Farmed Mink (Neovison vison) , 2020, Veterinary pathology.
[106] X. de Lamballerie,et al. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model , 2020, Nature Communications.
[107] M. Beer,et al. SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study , 2020, The Lancet Microbe.
[108] J. Knoblich,et al. Human organoids: model systems for human biology and medicine , 2020, Nature Reviews Molecular Cell Biology.
[109] A. García-Sastre,et al. Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection , 2020, bioRxiv.
[110] Chuan Qin,et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques , 2020, Science.
[111] R. Baric,et al. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice , 2020, Cell Reports.
[112] Jessie Huang,et al. SARS-CoV-2 Infection of Pluripotent Stem Cell-derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response , 2020, bioRxiv.
[113] C. Yao,et al. SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery , 2020, bioRxiv.
[114] W. Petri,et al. Evaluation of K18-hACE2 Mice as a Model of SARS-CoV-2 Infection , 2020, bioRxiv.
[115] P. Brun,et al. Ocular Surface Expression of SARS-CoV-2 Receptors , 2020, Ocular immunology and inflammation.
[116] Joshua L. Moore,et al. Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure , 2020, bioRxiv.
[117] Tokiko Watanabe,et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development , 2020, Proceedings of the National Academy of Sciences.
[118] J. Flynn,et al. SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and shedding of infectious virus from both respiratory and gastrointestinal tracts , 2020, bioRxiv.
[119] S. Weaver,et al. “Acute Respiratory Distress and Cytokine Storm in Aged, SARS-CoV-2 Infected African Green Monkeys, but not in Rhesus Macaques” , 2020, bioRxiv.
[120] Amogelang R. Raphenya,et al. Isolation, Sequence, Infectivity, and Replication Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Emerging infectious diseases.
[121] R. Field,et al. The SARS-COV-2 Spike Protein Binds Sialic Acids and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device , 2020, ACS central science.
[122] Larissa B. Thackray,et al. A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies , 2020, Cell.
[123] Rongchang Chen,et al. Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment , 2020, Cell.
[124] A. Gruber,et al. Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters , 2020, bioRxiv.
[125] C. Hallam,et al. SARS-CoV-2 infection leads to acute infection with dynamic cellular and inflammatory flux in the lung that varies across nonhuman primate species , 2020, bioRxiv.
[126] M. Koopmans,et al. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[127] F. Yu,et al. SARS-CoV-2 infection and stem cells: Interaction and intervention , 2020, Stem Cell Research.
[128] Kwok-Hung Chan,et al. Long SARS-CoV-2 nucleocapsid sequences in blood monocytes collected soon after hospital admission , 2020, bioRxiv.
[129] Kazuo Takayama. In Vitro and Animal Models for SARS-CoV-2 research , 2020, Trends in Pharmacological Sciences.
[130] Matthew J. O’Meara,et al. Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19 , 2020, bioRxiv.
[131] Lisa E. Gralinski,et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract , 2020, Cell.
[132] T. Zhao,et al. A Mouse Model of SARS-CoV-2 Infection and Pathogenesis , 2020, Cell Host & Microbe.
[133] Eun Ji Kim,et al. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets , 2020, mBio.
[134] P. Zhou,et al. Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2 , 2020, Cell.
[135] P. Sorger,et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques , 2020, Science.
[136] S. Ciesek,et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets , 2020, Nature.
[137] D. Chu,et al. Infection of dogs with SARS-CoV-2 , 2020, Nature.
[138] H. Yen,et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters , 2020, Nature.
[139] M. Veit,et al. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts , 2020, Journal of Virology.
[140] Y. Kawaoka,et al. Transmission of SARS-CoV-2 in Domestic Cats. , 2020, The New England journal of medicine.
[141] O. Tsang,et al. Infection of bat and human intestinal organoids by SARS-CoV-2 , 2020, Nature Medicine.
[142] H. Chen,et al. SARS-CoV-2 activates lung epithelia cell proinflammatory signaling and leads to immune dysregulation in COVID-19 patients by single-cell sequencing , 2020, medRxiv.
[143] E. Fischer,et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2 , 2020, Nature.
[144] Malik Peiris,et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures , 2020, The Lancet Respiratory Medicine.
[145] V. Jhanji,et al. Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea , 2020, Eye.
[146] Wenling Wang,et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice , 2020, Nature.
[147] Fang Li,et al. Cell entry mechanisms of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.
[148] Xiangxi Wang,et al. Development of an inactivated vaccine candidate for SARS-CoV-2 , 2020, Science.
[149] Jared L. Johnson,et al. Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids , 2020, bioRxiv.
[150] R. Schwartz,et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.
[151] Xiaozhong Peng,et al. Susceptibility of tree shrew to SARS-CoV-2 infection , 2020, Scientific Reports.
[152] Juan F Burgueño,et al. Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD , 2020, Inflammatory bowel diseases.
[153] Hans Clevers,et al. SARS-CoV-2 productively infects human gut enterocytes , 2020, Science.
[154] S. Allison. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2 , 2020, Nature Reviews Nephrology.
[155] André Machado Siqueira,et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.
[156] O. Tsang,et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study , 2020, The Lancet Microbe.
[157] V. Cagno,et al. SARS-CoV-2 cellular tropism , 2020, The Lancet Microbe.
[158] Koichi Yuki,et al. COVID-19 pathophysiology: A review , 2020, Clinical Immunology.
[159] Natacha S. Ogando,et al. SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology , 2020, bioRxiv.
[160] S. Ciesek,et al. Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection , 2020 .
[161] T. Kuiken,et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model , 2020, Science.
[162] Martin Stahl,et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 , 2020, Cell.
[163] M. Koopmans,et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets , 2020, bioRxiv.
[164] Li Yang,et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids , 2020, Protein & Cell.
[165] S. Anzick,et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 , 2020, Nature.
[166] Donald E. Ingber,et al. Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics , 2020 .
[167] Kohei Oishi,et al. Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics , 2020, bioRxiv.
[168] Zhanju Liu,et al. Clinical Features of COVID-19-Related Liver Functional Abnormality , 2020, Clinical Gastroenterology and Hepatology.
[169] Baoying Huang,et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2 , 2020, Science.
[170] J. Aronson,et al. Chloroquine and hydroxychloroquine in covid-19 , 2020, BMJ.
[171] Xiaotao Lu,et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice , 2020, Science Translational Medicine.
[172] Eun-Ha Kim,et al. Infection and Rapid Transmission of SARS-CoV-2 in Ferrets , 2020, Cell Host & Microbe.
[173] V. Soldatov,et al. On the way from SARS-CoV-sensitive mice to murine COVID-19 model , 2020 .
[174] Roland Eils,et al. SARS‐CoV‐2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells , 2020, The EMBO journal.
[175] E. Chorin,et al. The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin , 2020, medRxiv.
[176] Y. Yazdanpanah,et al. Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia , 2020, bioRxiv.
[177] Kaili Wu,et al. Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China , 2020, JAMA ophthalmology.
[178] Lu Lu,et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion , 2020, Cell Research.
[179] K. Hashimoto,et al. Nervous system involvement after infection with COVID-19 and other coronaviruses , 2020, Brain, Behavior, and Immunity.
[180] Yan Liu,et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.
[181] K. To,et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[182] Yuan Wei,et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.
[183] Zhìhóng Hú,et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.
[184] Jun Zheng. SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat , 2020, International journal of biological sciences.
[185] H. Gao,et al. Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques , 2020, Nature Communications.
[186] H. Gao,et al. Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2 , 2020, bioRxiv.
[187] Fumihiro Kato,et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells , 2020, Proceedings of the National Academy of Sciences.
[188] Frank Grosveld,et al. A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.
[189] Vineet D. Menachery,et al. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States , 2020, Emerging infectious diseases.
[190] Xu Liu,et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[191] X. de Lamballerie,et al. Of chloroquine and COVID-19 , 2020, Antiviral Research.
[192] Xiang Xie,et al. COVID-19 and the cardiovascular system , 2020, Nature Reviews Cardiology.
[193] Philippe Brouqui,et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 , 2020, International Journal of Antimicrobial Agents.
[194] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[195] Shinji Makino,et al. Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient , 2020, bioRxiv.
[196] Daniel Bell. SARS-CoV , 2020, Radiopaedia.org.
[197] P. Zhou,et al. Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques , 2020, Cell Research.
[198] Taojiao Wang,et al. Caution on Kidney Dysfunctions of COVID-19 Patients , 2020, medRxiv.
[199] Wenling Wang,et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice , 2020, Nature.
[200] Gengfu Xiao,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[201] Ralph S. Baric,et al. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.
[202] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[203] Jian-Piao Cai,et al. Human coronavirus dependency on host heat shock protein 90 reveals an antiviral target , 2020, Emerging microbes & infections.
[204] J. Penninger,et al. Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells , 2020, Emerging microbes & infections.
[205] N. Yaegashi,et al. Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals , 2020, The veterinary quarterly.
[206] A. García-Sastre,et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection , 2020, Emerging microbes & infections.
[207] H. Clevers,et al. Organoids in immunological research , 2019, Nature Reviews Immunology.
[208] A. Walls,et al. Structural basis for human coronavirus attachment to sialic acid receptors , 2019, Nature Structural & Molecular Biology.
[209] Jamie Munro,et al. Trends in clinical success rates and therapeutic focus , 2019, Nature Reviews Drug Discovery.
[210] C. Wang,et al. Phenotypic characterization of a novel type 2 diabetes animal model in a SHANXI MU colony of Chinese hamsters , 2019, Endocrine.
[211] Yuanyuan Han,et al. Tree shrew, a potential animal model for hepatitis C, supports the infection and replication of HCV in vitro and in vivo , 2017, The Journal of general virology.
[212] T. Tumpey,et al. Complexities in Ferret Influenza Virus Pathogenesis and Transmission Models , 2016, Microbiology and Molecular Reviews.
[213] Lisa E. Gralinski,et al. SARS-like WIV1-CoV poised for human emergence , 2016, Proceedings of the National Academy of Sciences.
[214] R. Dijkman,et al. Coronaviruses and the human airway: a universal system for virus-host interaction studies , 2016, Virology Journal.
[215] N. Sardesai,et al. A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates , 2015, Science Translational Medicine.
[216] Ulas Bagci,et al. Evaluation of candidate vaccine approaches for MERS-CoV , 2015, Nature Communications.
[217] R. A. Karssemeijer,et al. A 3-D enteroid-based model to study T-cell and epithelial cell interaction. , 2015, Journal of immunological methods.
[218] H. Goossens,et al. Culturing of respiratory viruses in well-differentiated pseudostratified human airway epithelium as a tool to detect unknown viruses , 2014, Influenza and other respiratory viruses.
[219] Krystal L. Matthews,et al. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. , 2014, The Journal of general virology.
[220] L. Poon,et al. Entry of Influenza A Virus with a α2,6-Linked Sialic Acid Binding Preference Requires Host Fibronectin , 2012, Journal of Virology.
[221] R. Baric,et al. Molecular Determinants of Severe Acute Respiratory Syndrome Coronavirus Pathogenesis and Virulence in Young and Aged Mouse Models of Human Disease , 2011, Journal of Virology.
[222] K. Schughart,et al. TMPRSS2 and TMPRSS4 Facilitate Trypsin-Independent Spread of Influenza Virus in Caco-2 Cells , 2010, Journal of Virology.
[223] J. Orenstein,et al. Human airway epithelial cell culture to identify new respiratory viruses: Coronavirus NL63 as a model , 2008, Journal of Virological Methods.
[224] Andrew Pekosz,et al. An immunosuppressed Syrian golden hamster model for SARS-CoV infection , 2008, Virology.
[225] Kate E. Jones,et al. Global trends in emerging infectious diseases , 2008, Nature.
[226] Qianjun Li,et al. The SARS-CoV ferret model in an infection–challenge study , 2008, Virology.
[227] Ron A M Fouchier,et al. Immunopathology and Infectious Disease Human and Avian Influenza Viruses Target Different Cells in the Lower Respiratory Tract of Humans and Other Mammals , 2010 .
[228] Amy C. Sims,et al. SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium , 2007, Virus Research.
[229] Jiang Gu,et al. Pathology and Pathogenesis of Severe Acute Respiratory Syndrome , 2007, The American Journal of Pathology.
[230] David K. Meyerholz,et al. Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus , 2006, Journal of Virology.
[231] C. Schwegmann-Wessels,et al. Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus. , 2006, The Journal of general virology.
[232] T. Greenough,et al. Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters , 2006, The Journal of infectious diseases.
[233] Lucy A. Perrone,et al. Apical Entry and Release of Severe Acute Respiratory Syndrome-Associated Coronavirus in Polarized Calu-3 Lung Epithelial Cells , 2005, Journal of Virology.
[234] T. Greenough,et al. Pneumonitis and Multi-Organ System Disease in Common Marmosets (Callithrix jacchus) Infected with the Severe Acute Respiratory Syndrome-Associated Coronavirus , 2005, The American Journal of Pathology.
[235] Krishna Shankara Narayanan,et al. Exogenous ACE2 Expression Allows Refractory Cell Lines To Support Severe Acute Respiratory Syndrome Coronavirus Replication , 2005, Journal of Virology.
[236] B. Murphy,et al. Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters , 2005, Journal of Virology.
[237] John A. Maher,et al. The Ferret: An Animal Model to Study Influenza Virus , 2004, Lab Animal.
[238] R. Sanchez,et al. The current and future organisational structure of the OIE (World Organisation for Animal Health) , 2003 .
[239] Albert D. M. E. Osterhaus,et al. SARS virus infection of cats and ferrets , 2003, Nature.
[240] Wilson Smith,et al. A Virus obtained from influenza patients , 1933 .
[241] World Health Organization,et al. Transmission of SARS-CoV-2: implications for infection prevention precautions , 2020 .
[242] Jacob D. Jaffe,et al. Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.
[243] K. B. Renegar. Influenza virus infections and immunity: a review of human and animal models. , 1992, Laboratory animal science.
[244] P. Demoly,et al. [Transgenic mice]. , 1992, Annales de dermatologie et de venereologie.